CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
FiercePharma21h
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
BioSpace4d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
fingerlakes14d
FDA approves first new non-opioid painkiller in 20 years
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
Oncology Nurse Advisor6d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Chemistry World1d
New type of painkiller approved in US
For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).
Miami Herald6d
CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
proudly congratulates and announces its role in supporting Vertex Pharmaceuticals' clinical studies that led to the FDA approval of JOURNAVX™ (suzetrigine), the first-in-class, non-opioid oral ...
Yale Daily News6d
First FDA-approved non-addictive painkiller has Yale roots
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.